9 RESULTS
COMMENT As a co-author on the study from the ARIC cohort by Walker et al., I was impressed when I first saw the data, how important midlife hypertension was, particularly in relation to hypertension appearing first in late life, and of course in relation to ...
COMMENT This set of three cases is interesting and raises concerns for people who had dural transplants before the practice ended. That said, these cases do not prove causality, and the authors acknowledge alternative hypotheses. One might have proposed it was ...
COMMENT This fully powered, 18-month study of nilvadipine (NILVAD) by Brian Lawlor and colleagues in persons with clinically diagnosed AD dementia failed to show any cognitive or functional benefits of NILVAD. The trial was well-designed and the published report ...
COMMENT This study represents the 36-month follow-up of a group of individuals in the AD spectrum who initially underwent Amyvid imaging as part of an Avid Pharmaceuticals-sponsored trial. As was expected from many studies using 11C PiB, the authors found that ...
COMMENT I am excited that an amyloid imaging agent will now be available because there are instances where my patients, their families, and I would appreciate the specific information about Alzheimer's disease that it would provide. My hope is that ordering ...
COMMENT Power et al. have conducted a systematic review of studies of the associations of hypertension and incident Alzheimer's disease. Their bottom line is that their analysis does not offer either convincing support or refutation of the association. I ...
COMMENT Schneider et al. present a reanalysis of three studies of memantine in mild to moderate Alzheimer’s disease (AD) in which they were able to isolate the data for the mild subjects. They find no benefits for memantine in milder AD dementia patients. ...
COMMENT This adverse effect of cholinesterase inhibitors is well known, but to the extent that it is uncommon, it may be underappreciated. Cholinesterase inhibitors would be expected to cause decreased conduction through the sinoatrial node and to suppress the ...
COMMENT A group of researchers at the Arizona Alzheimer’s Consortium led by Richard Caselli and Eric Reiman have been recruiting and following a large number of middle-aged persons who are either heterozygous or homozygous for the ApoE ε4 allele. Their current ...
